Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Novavax COVID-19-Influenza Combination Vaccine
NCT05519839Phase 2Completed
- Sponsor
- Novavax
- Start
- Dec 2022
- Primary completion
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, single-blind trial of qNIV + CoV2373 in coronavirus disease 2019 (COVID-19) and influenza (21 arms), sponsored by Novavax. Primary endpoints: Number of participants with solicited local and systemic Adverse Events (AEs), Percentage of participants with all AEs and 1 more. Started Dec 2022; status: completed.
02
Drugs
qNIV + CoV2373
03
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on NCT05519839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05519839.